Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers

Monday, November 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Compass Pathways and the Depression and Bipolar Support Alliance released a report detailing the impact of treatment-resistant depression (TRD) on patients and caregivers. The national survey included responses from 261 individuals with TRD and 73 caregivers, highlighting the significant daily challenges faced by those affected. The findings aim to inform better treatment options in mental health care.

Market Sentiment Analysis

POSITIVE FACTORS

  • New report highlights the burden of treatment-resistant depression.
  • Survey includes insights from patients and caregivers.
  • Partnership with DBSA enhances credibility of findings.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+172%
120-day peak, hindsight
Typical move
8.6%
average across 3 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
COMP360
Phase 3 · Treatment Resistant Depression

Full Press Release Details

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partnership with the Depression and Bipolar Support Alliance (DBSA), today released a new report summarizing findings from a national survey of people living with TRD (n=261) and caregivers (n=73) on the self-reported realities of living with a condition that can profoundly affect daily life, revealing th

Frequently Asked Questions

Who conducted the survey?

Compass Pathways partnered with the Depression and Bipolar Support Alliance to release the report.

How many patients participated?

The national survey included 261 people living with treatment-resistant depression.

How many caregivers joined?

The study also surveyed 73 caregivers regarding their experiences with the condition.

What does the report cover?

It reveals the self-reported realities and lived burden of treatment-resistant depression on daily life.

ShareAdd on Google
Tags: CMPS Compass Pathways DBSA treatment-resistant depression mental health patient survey
Last updated: Nov 2, 2026

Biotech snapshot

Cash runway
$433M liquidity · $13M/mo burn
~30 mo
Minimal dilution risk
Lead asset
COMP360Phase 3
Treatment Resistant Depression →

Catalyst track record

+172%
best trade around CMPS's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for CMPS.

See every catalyst's timing & PoA →